Summit Therapeutics Inc. (SMMT)

Market Cap	15.20B
Revenue (ttm)	n/a
Net Income (ttm)	-221.32M
Shares Out	737.68M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,628,420
Open	20.06
Previous Close	19.89
Day's Range	19.70 - 20.79
52-Week Range	2.10 - 33.89
Beta	-1.04
Analysts	Strong Buy
Price Target	35.44 (+72.04%)
Earnings Date	Apr 30, 2025

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. Its lead development candidate, ivonescimab, is a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and is also in Phase III clinical trials for the treatment of non-small lung cancer. The company has a collaboration and license agreement with Akeso, Inc. and its affiliates ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: SMMT
• Website: https://www.summittxinc.com

Analyst Forecast

According to 10 analysts, the average rating for SMMT stock is "Strong Buy." The 12-month stock price forecast is $35.44, which is an increase of 72.04% from the latest price.

Price Target

$35.44

(72.04% upside)

Analyst Consensus: Strong Buy